Additional 1.6 mio. Packs of Paracetamol by Darnitsa

More than 1.6 mio. packs of the medicinal product “Paracetamol-Darnitsa” will be supplied to Ukrainian pharmacies in the course of a month. Darnitsa Pharmaceutical Company commenced the production of new batches of the medicinal product.

The global statistics shows that nearly 80% of those infected with COVID-19 come through the illness in a mild form, while staying at home. The National Health Service of the United Kingdom published the recommendations for treatment of coronavirus symptoms at home, where patients with COVID-19 are advised to take Paracetamol in order to keep the fever down – one of the key symptoms of the coronavirus infection.

This resulted in the increased demand for medicinal products containing Paracetamol.

Dmytro Shymkiv, Chairman of the Board of Directors of Darnitsa Group:

“We keep an eye on the development of the COVID-19 epidemic in Ukraine and study the experience of our colleagues from other countries to respond quickly to the growing need for drugs to treat coronavirus symptoms. Most national treatment protocols of the EU countries recommend Paracetamol as the drug of choice for treatment of fever and pain. Therefore, in March, we supplied 1 million packs of “Paracetamol-Darnitsa” to pharmacies, and in April we continue the production of this effective and affordable medicine. In the course of the month, Darnitsa will additionally ship more than 1.6 million packs.”

“Paracetamol-Darnitsa” is a medicinal product with antipyretic and moderate analgesic action. It is available in tablets with the dosage strengths of 200 mg and 500 mg, marketing authorizations UA 4369/01/01 and 4369/01/03. The site where “Paracetamol-Darnitsa” is manufactured meets international standards of good manufacturing practice (GMP).